Prothena (PRTA) Competitors $8.72 -0.48 (-5.22%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$8.93 +0.21 (+2.40%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA vs. MIRM, BHC, BEAM, GMTX, NAMS, VCEL, BLTE, TARS, JANX, and SDGRShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Mirum Pharmaceuticals (MIRM), Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Gemini Therapeutics (GMTX), NewAmsterdam Pharma (NAMS), Vericel (VCEL), Belite Bio (BLTE), Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical products" industry. Prothena vs. Mirum Pharmaceuticals Bausch Health Companies Beam Therapeutics Gemini Therapeutics NewAmsterdam Pharma Vericel Belite Bio Tarsus Pharmaceuticals Janux Therapeutics Schrödinger Prothena (NASDAQ:PRTA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations. Which has stronger earnings & valuation, PRTA or MIRM? Prothena has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProthena$135.16M3.47-$147.03M-$2.30-3.79Mirum Pharmaceuticals$336.89M6.37-$163.41M-$1.85-23.47 Do insiders & institutionals believe in PRTA or MIRM? 97.1% of Prothena shares are held by institutional investors. 9.2% of Prothena shares are held by company insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is PRTA or MIRM more profitable? Mirum Pharmaceuticals has a net margin of -31.69% compared to Prothena's net margin of -90.50%. Prothena's return on equity of -22.67% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Prothena-90.50% -22.67% -19.68% Mirum Pharmaceuticals -31.69%-41.22%-14.81% Does the MarketBeat Community favor PRTA or MIRM? Prothena received 480 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 75.86% of users gave Mirum Pharmaceuticals an outperform vote while only 70.43% of users gave Prothena an outperform vote. CompanyUnderperformOutperformProthenaOutperform Votes61270.43% Underperform Votes25729.57% Mirum PharmaceuticalsOutperform Votes13275.86% Underperform Votes4224.14% Does the media favor PRTA or MIRM? In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Prothena. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 6 mentions for Prothena. Mirum Pharmaceuticals' average media sentiment score of 1.57 beat Prothena's score of 0.72 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend PRTA or MIRM? Prothena presently has a consensus price target of $55.00, indicating a potential upside of 530.73%. Mirum Pharmaceuticals has a consensus price target of $58.20, indicating a potential upside of 34.04%. Given Prothena's higher probable upside, equities analysts plainly believe Prothena is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has more volatility & risk, PRTA or MIRM? Prothena has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500. SummaryMirum Pharmaceuticals beats Prothena on 13 of the 19 factors compared between the two stocks. Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$495.21M$6.85B$5.54B$7.93BDividend YieldN/A2.96%5.09%4.23%P/E Ratio-3.797.3222.5318.54Price / Sales3.47241.43399.57103.29Price / CashN/A65.8538.1834.62Price / Book0.836.486.774.25Net Income-$147.03M$143.41M$3.22B$248.18M7 Day Performance-10.10%1.91%1.11%0.91%1 Month Performance-28.17%4.28%2.50%2.58%1 Year Performance-60.44%-3.87%15.76%4.02% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena3.4234 of 5 stars$8.72-5.2%$55.00+530.7%-59.3%$495.21M$135.16M-3.79130Upcoming EarningsNews CoverageHigh Trading VolumeMIRMMirum Pharmaceuticals4.2422 of 5 stars$41.31+1.3%$58.20+40.9%+68.8%$2.04B$336.89M-20.45140Upcoming EarningsPositive NewsBHCBausch Health Companies4.1781 of 5 stars$5.41-0.6%$7.17+32.5%-39.5%$2.00B$9.63B-45.0819,900Analyst UpgradeBEAMBeam Therapeutics3.0729 of 5 stars$19.80+1.4%$49.45+149.8%-8.8%$1.99B$63.52M-11.25510Upcoming EarningsShort Interest ↑News CoverageGMTXGemini TherapeuticsN/A$45.42-1.6%N/A+73.2%$1.97BN/A-45.4230NAMSNewAmsterdam Pharma3.1676 of 5 stars$17.83+1.8%$43.33+143.0%-8.8%$1.96B$45.56M-6.864Positive NewsVCELVericel2.1572 of 5 stars$38.74-2.5%$60.86+57.1%-19.5%$1.94B$237.22M645.77300Upcoming EarningsPositive NewsBLTEBelite Bio2.9701 of 5 stars$60.18+3.3%$96.67+60.6%+50.9%$1.92BN/A-54.2210News CoveragePositive NewsTARSTarsus Pharmaceuticals2.0699 of 5 stars$49.72-0.6%$63.67+28.1%+54.8%$1.91B$182.95M-13.0550Earnings ReportUpcoming EarningsNews CoveragePositive NewsJANXJanux Therapeutics3.0204 of 5 stars$32.23+3.8%$95.25+195.5%-44.9%$1.90B$10.59M-27.5530Upcoming EarningsNews CoveragePositive NewsGap DownSDGRSchrödinger2.4635 of 5 stars$25.75-2.6%$33.00+28.2%-1.5%$1.88B$207.54M-11.00790Upcoming Earnings Related Companies and Tools Related Companies Mirum Pharmaceuticals Competitors Bausch Health Companies Competitors Beam Therapeutics Competitors Gemini Therapeutics Competitors NewAmsterdam Pharma Competitors Vericel Competitors Belite Bio Competitors Tarsus Pharmaceuticals Competitors Janux Therapeutics Competitors Schrödinger Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRTA Stock Free PRTA Stock Alerts